Sequence: CKRRMKWKK
| Experiment Id | EXP001424 |
|---|---|
| Paper | Cell-penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound triggered si |
| Peptide | Penetratin-derived CPP |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 10 mg/kg c-Myc siRNA (treatment, tail vein; days 6, 9, 12, 15). Imaging/biodistribution used 1.2 mg/kg Cy3-siRNA. |
| Mixing Ratio | YSA-NB surface: DSPE-PEG2000-YSA + DSPE-PEG2000 (5:5 molar, total PEGylated lipid 10); DPPC/DSPC/PEGylated lipid = 90/10/10 (molar ratio); perfluorobutane (C3F8) gas core; EE ~86.41% |
| Formulation Format | CPP–siRNA/YSA-NB (+US) |
| Formulation Components | CPP–siRNA conjugate (disulfide-linked; reducible by cytosolic GSH) in YSA-modified nanobubbles; tumor-site ultrasound 1 MHz; Ispta 1 W/cm^2; 10 s on/10 s off for total 60 s |
| Size Nm | 203.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c nude mice with MCF-7 (EphA2-positive) xenograft tumors (subcutaneous) |
| Administration Route | Intravenous (tail vein) + local tumor ultrasound 30 min post-injection |
| Output Type | In vivo functional delivery: tumor growth inhibition (relative tumor volume / T/C%), tumor c-Myc mRNA (qRT-PCR) and protein (Western blot) |
| Output Value | |
| Output Units | |
| Output Notes | Strongest tumor growth inhibition and best c-Myc silencing observed with CPP–siRNA/YSA-NB combined with ultrasound. |
| Toxicity Notes | No significant body weight loss reported during treatment regimen. |
| Curation Notes |